Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS 2 | AUG 10 | Time limit for inactive STN sessions doubles to 40 minutes |
| NEWS 3 | AUG 18 | COMPENDEX indexing changed for the Corporate Source (CS) field |
| NEWS 4 | AUG 24 | ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced |
| NEWS 5 | AUG 24 | CA/CAplus enhanced with legal status information for U.S. patents |
| NEWS 6 | SEP 09 | 50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY |
| NEWS 7 | SEP 11 | WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus |
| NEWS 8 | OCT 21 | Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded |
| NEWS 9 | OCT 21 | Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models |
| NEWS 10 | NOV 23 | Addition of SCAN format to selected STN databases |
| NEWS 11 | NOV 23 | Annual Reload of IFI Databases |
| NEWS 12 | DEC 01 | FRFULL Content and Search Enhancements |
| NEWS 13 | DEC 01 | DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets |
| NEWS 14 | DEC 02 | Derwent World Patent Index: Japanese FI-TERM thesaurus added |
| NEWS 15 | DEC 02 | PCTGEN enhanced with patent family and legal status display data from INPADOCDB |
| NEWS 16 | DEC 02 | USGENE: Enhanced coverage of bibliographic and sequence information |
| NEWS 17 | DEC 21 | New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/CAplus |
| NEWS 18 | JAN 12 | Match STN Content and Features to Your Information Needs, Quickly and Conveniently |
| NEWS 19 | JAN 25 | Annual Reload of MEDLINE database |
| NEWS 20 | FEB 16 | STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download |
| NEWS 21 | FEB 16 | Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts |
| NEWS 22 | FEB 16 | New FASTA Display Formats Added to USGENE and PCTGEN |
| NEWS 23 | FEB 16 | INPADOCDB and INPAFAMDB Enriched with New Content and Features |
| NEWS 24 | FEB 16 | INSPEC Adding Its Own IPC codes and Author's E-mail Addresses |

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

```
 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:53:25 ON 17 MAR 2010

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.22       0.22

FILE 'REGISTRY' ENTERED AT 16:53:38 ON 17 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   16 MAR 2010  HIGHEST RN 1210608-68-6
DICTIONARY FILE UPDATES:  16 MAR 2010  HIGHEST RN 1210608-68-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10758589_NEW.str
```



```
chain nodes :
7  8  9  10  11  12  13  14  15  22  23  24  25  26  27
ring nodes :
1  2  3  4  5  6  16  17  18  19  20  21
chain bonds :
6-7  7-8  7-24  8-9  8-26  9-10  10-11  10-22  11-12  12-13  12-23  13-14  14-15
14-27  15-16  15-25
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  16-17  16-21  17-18  18-19  19-20  20-21
exact/norm bonds :
7-8  7-24  8-9  9-10  10-22  12-13  12-23  13-14  14-15  15-25
exact bonds :
6-7  8-26  10-11  11-12  14-27  15-16
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  16-17  16-21  17-18  18-19  19-20  20-21


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
 11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:Atom  17:Atom  18:Atom
19:Atom  20:Atom  21:Atom  22:CLASS  23:CLASS  24:CLASS  25:CLASS  26:CLASS
27:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss
SAMPLE SEARCH INITIATED 16:54:17 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       15 TO ITERATE

100.0% PROCESSED       15 ITERATIONS                                2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:           68 TO       532
```

PROJECTED ANSWERS:  2 TO  124

L2  2 SEA SSS SAM L1

=> d l2 1-2

L2  ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2010 ACS on STN
RN  1008758-35-7  REGISTRY
ED  Entered STN:  18 Mar 2008
CN  Propanedioic acid, 1,3-bis[2-[(4-methoxyphenyl)thioxomethyl]-2-methylhydrazide], potassium salt (1:2)  (CA INDEX NAME)
MF  C21 H24 N4 O4 S2 . 2 K
SR  CA
LC  STN Files:  CA, CAPLUS, TOXCENTER, USPATFULL
CRN  (488832-83-3)



●2 K

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2  ANSWER 2 OF 2  REGISTRY  COPYRIGHT 2010 ACS on STN
RN  488833-02-9  REGISTRY
ED  Entered STN:  12 Feb 2003
CN  Propanedioic acid, 1,3-bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide]  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN  Propanedioic acid, bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (9CI)
DR  1008757-56-9
MF  C23 H28 N4 O2 S2
CI  COM
SR  CA
LC  STN Files:  CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

17 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
17 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s l1 exa
SAMPLE SEARCH INITIATED 16:54:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED        0 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:            0 TO        0
PROJECTED ANSWERS:               0 TO        0

L3            0 SEA EXA SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 191.05 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 16:54:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      389 TO ITERATE

100.0% PROCESSED      389 ITERATIONS                               102 ANSWERS
SEARCH TIME: 00.00.01

L4          102 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   196.23     196.45

FILE 'CAPLUS' ENTERED AT 16:54:56 ON 17 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 17 Mar 2010  VOL 152 ISS 12
FILE LAST UPDATED: 16 Mar 2010  (20100316/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Dec 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.
```

```
=> s l4
L5          36 L4

=> s l5 and (?cancer? or ?tumor? or ?tumour? or ?neoplasm?)/ti
        215565 ?CANCER?/TI
        188206 ?TUMOR?/TI
          6861 ?TUMOUR?/TI
          6861 ?TUMOUR?/TI
        194994 ?TUMOR?/TI
                 ((?TUMOR? OR ?TUMOUR?)/TI)
          6861 ?TUMOUR?/TI
        188206 ?TUMOR?/TI
        188206 ?TUMOR?/TI
        194994 ?TUMOUR?/TI
                 ((?TUMOUR? OR ?TUMOR?)/TI)
          5017 ?NEOPLASM?/TI
L6          11 L5 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM?)/TI

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7           11 DUP REM L6 (0 DUPLICATES REMOVED)

=> d l7 1-11 ibib abs

L7   ANSWER 1 OF 11  CAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         2009:707534  CAPLUS
DOCUMENT NUMBER:          151:42041
TITLE:                    Polymorphs of N-malonyl-bis(N'-methyl-N'-
                          thiobenzoylhydrazide) and compositions for treatment
                          of cancer
INVENTOR(S):              Kostik, Elena I.; Sun, Lijun; Dziewiszek, Joanna;
                          Choi, Jun Y.
PATENT ASSIGNEE(S):       Synta Pharmaceuticals Corp., USA
SOURCE:                   PCT Int. Appl., 100pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
     WO 2009073148        A2    20090611    WO 2008-US13204        20081128
     WO 2009073148        A3    20091015
          W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
              CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
              FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
              KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
              ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
              PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
              TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
          RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
              IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
              TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
              TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
              AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.:                        US 2007-4476P       P  20071128
                                              US 2007-4740P       P  20071129
AB   The invention relates to crystalline forms of
     N-malonyl-bis(N'-methyl-N'-thiobenzoylhydrazide) (Compound 1).  At least 70%
     by weight of Compound 1 is the single crystalline form, Form A, Form C, or
Form D of
```

the compound A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent, and Compound 1, wherein at least 70% by weight of the compound is the single crystalline form, Form A, Form C, or Form D of the compound is provided. A method of treating a subject with cancer, especially melanoma, comprises administering to the subject an effective amount of compound 1 or the pharmaceutical composition thereof, in combination with an effective amount of paclitaxel or a paclitaxel analog. Thus, 5 g of Compound 1 was dissolved in 1350 mL of dichloromethane, cooled to 0° and agitated for 12-16 h. The resulting solid was filtered, washed and dried to give Form C of Compound 1 (yield 3-3.5 g).

L7 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:831279 CAPLUS
DOCUMENT NUMBER: 149:160584
TITLE: Method for treating cancer comprising administering compound that increases oxidative stress of cancer cells and activates p38
INVENTOR(S): Betin, John; Kirshner, Jessica R.; Du, Zhenjian
PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA
SOURCE: PCT Int. Appl., 124pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2008082579 | A1 | 20080710 | WO 2007-US26343 | 20071227 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| US 20090093538 | A1 | 20090409 | US 2007-5654 | 20071227 |

PRIORITY APPLN. INFO.: US 2007-878557P P 20070103
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 149:160584
GI




I

AB The invention relates to a method of treating cancer in a subject, comprising administering to the subject an anti-cancer therapy and a compound that increases the oxidative stress of the cancer cells and

activates p38, such as compound (I). It is related to the discovery that the efficacy of standard treatments for cancer, such as chemotherapy or radiation treatment, can be increased by administering them in combination with an agent that increase the oxidative stress of cancer cells by inhibiting the mechanisms that cancer cells utilize to compensate for ROS and/or activating cellular signaling pathways that lead to immunocytotoxicity. Thus, formulation comprising paclitaxel (5 mg/kg) + compound I (50 mg/kg) significantly enhanced antitumor activity of paclitaxel on human breast tumor MDA-MB-435 in nude mice, without increasing toxicity.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:285694 CAPLUS
DOCUMENT NUMBER: 148:299878
TITLE: Combination with bis(thiohydrazide amides) for treating cancer
INVENTOR(S): Koya, Keizo
PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA
SOURCE: PCT Int. Appl., 125pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2008027445 | A2 | 20080306 | WO 2007-US19021 | 20070830 |
| WO 2008027445 | A3 | 20080626 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | |
| AU 2007290490 | A1 | 20080306 | AU 2007-290490 | 20070830 |
| US 20080119440 | A1 | 20080522 | US 2007-897538 | 20070830 |
| EP 2076254 | A2 | 20090708 | EP 2007-837506 | 20070830 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS | | | | |
| JP 2010502616 | T | 20100128 | JP 2009-526701 | 20070830 |
| PRIORITY APPLN. INFO.: | | | US 2006-841570P P | 20060831 |
| | | | WO 2007-US19021 W | 20070830 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 148:299878
AB Disclosed herein are methods of treating a proliferative disease, such as cancer, with bis(thio-hydrazide amides) or a tautomer, pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, in combination with hyperthermia treatment. Also disclosed are methods of treating a proliferative disease, such as cancer, with bis(thio-hydrazide amides) or a tautomer, pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, in combination with radiotherapy.
OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD

(1 CITINGS)

L7 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:256009 CAPLUS
DOCUMENT NUMBER: 148:299872
TITLE: Bis(thiohydrazide amide) combination with immunotherapy for treating cancer
INVENTOR(S): Jacobson, Eric
PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA
SOURCE: PCT Int. Appl., 143pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2008024299 | A2 | 20080228 | WO 2007-US18354 | 20070820 |
| WO 2008024299 | A3 | 20080417 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | |
| AU 2007288334 | A1 | 20080228 | AU 2007-288334 | 20070820 |
| EP 2059236 | A2 | 20090520 | EP 2007-811430 | 20070820 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS | | | | |
| JP 2010501558 | T | 20100121 | JP 2009-525581 | 20070820 |
| PRIORITY APPLN. INFO.: | | | US 2006-839113P P | 20060821 |
| | | | WO 2007-US18354 W | 20070820 |

OTHER SOURCE(S): MARPAT 148:299872
AB The invention discloses methods for treating an immunosensitive cancer with bis(thiohydrazide amides), or pharmaceutically acceptable salts thereof, and an immunotherapy. Compds. of the invention include e.g. PhC(S)N(Me)NHC(O)CH2C(O)NHN(Me)C(S)Ph.

L7 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1017205 CAPLUS
DOCUMENT NUMBER: 149:282666
TITLE: Elesclomol induces cancer cell apoptosis through oxidative stress
AUTHOR(S): Kirshner, Jessica R.; He, Suqin; Balasubramanyam, Vishwasenani; Kepros, Jane; Yang, Chin-Yu; Zhang, Mei; Du, Zhenjian; Barsoum, James; Bertin, John
CORPORATE SOURCE: Synta Pharmaceuticals Corp., Lexington, MA, 02421, USA
SOURCE: Molecular Cancer Therapeutics (2008), 7(8), 2319-2327
CODEN: MCTOCF; ISSN: 1535-7163
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Elesclomol (formerly STA-4783) is a novel small mol. undergoing clin. evaluation in a pivotal phase III melanoma trial (SYMMETRY). In a phase

II randomized, double-blinded, controlled, multi-center trial in 81 patients with stage IV metastatic melanoma, treatment with elesclomol plus paclitaxel showed a statistically significant doubling of progression-free survival time compared with treatment with paclitaxel alone. Although elesclomol displays significant therapeutic activity in the clinic, the mechanism underlying its anticancer activity has not been defined previously. Here, we show that elesclomol induces apoptosis in cancer cells through the induction of oxidative stress. Treatment of cancer cells in vitro with elesclomol resulted in the rapid generation of reactive oxygen species (ROS) and the induction of a transcriptional gene profile characteristic of an oxidative stress response. Inhibition of oxidative stress by the antioxidant N-acetylcysteine blocked the induction of gene transcription by elesclomol. In addition, N-acetylcysteine blocked drug-induced apoptosis, indicating that ROS generation is the primary mechanism responsible for the proapoptotic activity of elesclomol. Excessive ROS production and elevated levels of oxidative stress are critical biochem. alterations that contribute to cancer cell growth. Thus, the induction of oxidative stress by elesclomol exploits this unique characteristic of cancer cells by increasing ROS levels beyond a threshold that triggers cell death. [Mol Cancer Ther 2008;7(8):2319-27].

OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:87076 CAPLUS

DOCUMENT NUMBER: 146:330123

TITLE: Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors

AUTHOR(S): Berkenblit, Anna; Eder, Joseph P., Jr.; Ryan, David P.; Seiden, Michael V.; Tatsuta, Noriaki; Sherman, Matthew L.; Dahl, Thomas A.; Dezube, Bruce J.; Supko, Jeffrey G.

CORPORATE SOURCE: Beth Israel Deaconess Medical Center, Boston, MA, USA

SOURCE: Clinical Cancer Research (2007), 13(2, Pt. 1), 584-590 CODEN: CCREF4; ISSN: 1078-0432

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB STA-4783 is a new compound that markedly enhances the therapeutic index of paclitaxel against human tumor xenograft models. A phase I clin. trial was undertaken to determine the maximum tolerated dose, toxicity profile, and pharmacokinetics of STA-4783 in combination with paclitaxel. Adults with refractory solid tumors concurrently received STA-4783 and paclitaxel as a 3-h i.v. infusion at starting doses of 44 and 135 mg/m2, resp. After increasing paclitaxel to 175 mg/m2, the STA-4783 dose was escalated as permitted by dose-limiting toxicity during the first 21-day cycle. Thirty-five patients were treated with eight dose levels of STA-4783/paclitaxel. In patients receiving 175 mg/m2 paclitaxel, the incidence of severe toxicity increased with escalation of the STA-4783 dose above 263 mg/m2, and 438 mg/m2 was the maximum tolerated dose. All toxicities were typical of paclitaxel, with neutropenia, mucositis, and myalgia/arthralgia being dose limiting. Partial responses were achieved in one patient with Kaposi's sarcoma and another with ovarian cancer that progressed during prior treatment with paclitaxel. STA-4783 exhibited linear pharmacokinetics characterized by rapid elimination from plasma (biol. half-life, 1.06 ± 0.24 h) and a low steady-state apparent volume of distribution (25.1 ± 8.1 L/m2). The total body clearance of paclitaxel decreased significantly with escalation of the STA-4783 dose. The STA-4783/paclitaxel combination was well tolerated with a toxicity

profile similar to single-agent paclitaxel. Enhanced systemic exposure to paclitaxel resulting from a dose-dependent interaction with STA-4783 was associated with increased toxicity. Objective responses in two heavily pretreated patients, both with taxane exposure, have encouraged further clin. evaluation of this regimen.

OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:1122626 CAPLUS

DOCUMENT NUMBER: 145:449186

TITLE: Combination cancer therapy with bis(thiohydrazide) amide compounds and taxanes

INVENTOR(S): Dahl, Thomas A.; McLeod, Matthew

PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 63pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2006113695 | A1 | 20061026 | WO 2006-US14531 | 20060413 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| AU 2006236378 | A1 | 20061026 | AU 2006-236378 | 20060413 |
| CA 2604907 | A1 | 20061026 | CA 2006-2604907 | 20060413 |
| EP 1877048 | A1 | 20080116 | EP 2006-750538 | 20060413 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| JP 2008536875 | T | 20080911 | JP 2008-506821 | 20060413 |
| ZA 2007008703 | A | 20081126 | ZA 2007-8703 | 20071011 |
| MX 2007012688 | A | 20080314 | MX 2007-12688 | 20071012 |
| US 20090137682 | A1 | 20090528 | US 2008-918357 | 20080825 |
| PRIORITY APPLN. INFO.: | | | US 2005-672139P P | 20050415 |
| | | | WO 2006-US14531 W | 20060413 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 145:449186

AB A method of treating a subject with cancer includes co-administering to the subject over 3-5 wk, a taxane in an amount of between about 243-315 μmol/m2 (e.g., equivalent to paclitaxel in about 210-270 mg/m2); and a bis(thiohydrazide amide) in an amount between about 1473-1722 μmol/m2. (e.g. PhC(S)N(Me)NHC(O)CH2C(O)NHN(Me)C(S)Ph in about 590-690 mg/m2). The bis(thiohydrazide amide) is represented by R1C(S)N(R3)N(R7)C(Z)YC(Z)N(R8)N(R4)C(S)R2 [Y = covalent bond, (un)substituted straight chain hydrocarbyl, or C(Z)YC(Z) forms (un)substituted aromatic group; R1-R4 = H, (un)substituted aliphatic group,

(un)substituted aryl group, etc.; R7, R8 = H, (un)substituted aliphatic group, (un)substituted aryl group; Z = O, S].
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:1124931 CAPLUS
DOCUMENT NUMBER: 145:449193
TITLE: Natural killer cell activity-based methods for determining prognosis for patients undergoing cancer therapy
INVENTOR(S): Barsoum, James; Du, Zhenjian; Dahl, Thomas A.; McLeod, Matthew
PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2006113493 | A2 | 20061026 | WO 2006-US14186 | 20060413 |
| WO 2006113493 | A3 | 20081231 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2005-671833P P 20050415
OTHER SOURCE(S): MARPAT 145:449193
AB A method of determining a prognosis for a subject undergoing cancer therapy with an agent that activates heat shock protein 70 (Hsp70) includes comparing natural killer (NK) cell activity in a test sample with NK cell activity in a control sample. The control sample can be taken from the subject before dosing with the agent and the test sample can be taken from the subject after dosing with the agent. An increase in NK cell activity in the test sample compared with the control sample can indicate an improved prognosis.
OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L7 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:75829 CAPLUS
DOCUMENT NUMBER: 144:170795
TITLE: Preparation of bis(thiohydrazide amide) salts for treatment of cancer
INVENTOR(S): Kostik, Elena; Vaghefi, Farid; Liang, Guiqing; Koya, Keizo; Sun, Lijun; Tatsuta, Noriaki; Chen, Shoujun; Inoue, Takayo; Xia, Zhi-Qiang
PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2006009940 | A1 | 20060126 | WO 2005-US21642 | 20050620 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| AU 2005265202 | A1 | 20060126 | AU 2005-265202 | 20050620 |
| AU 2005265202 | B2 | 20090723 | | |
| CA 2570698 | A1 | 20060126 | CA 2005-2570698 | 20050620 |
| US 20060135595 | A1 | 20060622 | US 2005-157213 | 20050620 |
| US 7385084 | B2 | 20080610 | | |
| EP 1781604 | A1 | 20070509 | EP 2005-762347 | 20050620 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU | | | | |
| CN 1993318 | A | 20070704 | CN 2005-80026445 | 20050620 |
| JP 2008504264 | T | 20080214 | JP 2007-518152 | 20050620 |
| BR 2005012526 | A | 20080311 | BR 2005-12526 | 20050620 |
| NZ 552159 | A | 20091224 | NZ 2005-552159 | 20050620 |
| ZA 2006010440 | A | 20071227 | ZA 2006-10440 | 20061213 |
| MX 2006015126 | A | 20080911 | MX 2006-15126 | 20061220 |
| IN 2007DN00172 | A | 20070803 | IN 2007-DN172 | 20070108 |
| NO 2007000378 | A | 20070316 | NO 2007-378 | 20070119 |
| KR 2007029259 | A | 20070313 | KR 2007-701513 | 20070122 |
| US 20080269340 | A1 | 20081030 | US 2008-148312 | 20080418 |
| US 7579503 | B2 | 20090825 | | |
| US 20090281172 | A1 | 20091112 | US 2009-503661 | 20090715 |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 2004-582596P | P | 20040623 |
| US 2005-681368P | P | 20050516 |
| US 2005-157213 | A1 | 20050620 |
| WO 2005-US21642 | W | 20050620 |
| US 2008-148312 | A1 | 20080418 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 144:170795
AB R1CSNR3N:C(Z-)YC(Z-):NNR4CSR2.2M+ [Y = bond, (substituted) hydrocarbylene; R1-R4 = H, (substituted) aliphatyl, aryl; R1R3, R2R4 = atoms to form non-aromatic heterocyclic ring optionally fused to aromatic ring; Z = O, S; M+ = pharmaceutically acceptable cation], were prepared Thus, (PhCSNMeNHCO)2CH2 was added to aqueous NaOH followed by freeze drying to give [PhCSNMeN:C(ONa)]2CH2. The latter showed H2O soly of >1000 mg/mL.
OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:633518 CAPLUS

DOCUMENT NUMBER: 141:173877
TITLE: A preparation of malonyl dihydrazide derivatives, useful for the treatment of multi-drug resistant cancer
INVENTOR(S): Koya, Keizo; Sun, Lijun; Wu, Yaming; Korbut, Timoty; Zhou, Dan; Du, Zhenjian; Chen, Shoujun; Tatsuta, Noriaki; Liang, Guiqing; Ono, Mitsunori
PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA
SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004064826 | A1 | 20040805 | WO 2004-US1089 | 20040115 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ | | | | |
| AU 2004206865 | A1 | 20040805 | AU 2004-206865 | 20040115 |
| AU 2004206865 | B2 | 20060713 | | |
| CA 2512797 | A1 | 20040805 | CA 2004-2512797 | 20040115 |
| US 20040225016 | A1 | 20041111 | US 2004-758589 | 20040115 |
| EP 1583524 | A1 | 20051012 | EP 2004-702560 | 20040115 |
| EP 1583524 | B1 | 20060823 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| JP 2006515626 | T | 20060601 | JP 2006-500976 | 20040115 |
| AT 336991 | T | 20060915 | AT 2004-702560 | 20040115 |
| PT 1583524 | E | 20061229 | PT 2004-702560 | 20040115 |
| ES 2271839 | T3 | 20070416 | ES 2004-702560 | 20040115 |
| HK 1084024 | A1 | 20070119 | HK 2006-104252 | 20060407 |
| AU 2006228035 | A1 | 20061102 | AU 2006-228035 | 20061011 |
| AU 2006228035 | B2 | 20100218 | | |

| PRIORITY APPLN. INFO.: | | |
|---|---|---|
| US 2003-440406P | P | 20030115 |
| AU 2004-206865 | A3 | 20040115 |
| WO 2004-US1089 | W | 20040115 |

OTHER SOURCE(S): MARPAT 141:173877
GI



I



II

AB One embodiment of the present invention is a method of treating a subject with a multi-drug resistant cancer. The method comprises administering to the subject an effective amount of a compound represented by formula I [wherein: Y is a covalent bond or (un)substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is (un)substituted aromatic group; R1-R4 are independently H, aliphatic group, substituted aliphatic group, or aryl group, etc.; R5 and R6 are independently H, aliphatic group, substituted aliphatic group, (un)substituted aryl group; Z is O or S]. For instance, malonyl dihydrazide derivative II (IC50 = 0.005 μM, multi-drug cell line MES-SA/DX5) was prepared via amidation of malonic acid by PhC(:S)N(Me)NH2 with a yield of 80% (example 4).

OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:818151 CAPLUS

DOCUMENT NUMBER: 139:323341

TITLE: Preparation of thiobenzoylhydrazide derivatives as taxol enhancers for treatment of cancer

INVENTOR(S): Koya, Keizo; Sun, Lijun; Chen, Shoujun; Tatsuta, Noriaki; Wu, Yaming; Ono, Mitsunori

PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA

SOURCE: U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 193,075.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20030195258 | A1 | 20031016 | US 2003-345885 | 20030115 |
| US 6924312 | B2 | 20050802 | | |
| US 20030045518 | A1 | 20030306 | US 2002-193639 | 20020710 |
| US 6762204 | B2 | 20040713 | | |
| US 20030119914 | A1 | 20030626 | US 2002-193075 | 20020710 |
| US 6800660 | B2 | 20041005 | | |
| EP 1731148 | A1 | 20061213 | EP 2006-19066 | 20020710 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR, AL, LT, LV, MK, RO, SI | | | | |
| EP 2100605 | A1 | 20090916 | EP 2009-4577 | 20020710 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR, AL, LT, LV, MK, RO, SI | | | | |
| ZA 2004001051 | A | 20050622 | ZA 2004-1051 | 20040209 |
| ZA 2004001054 | A | 20050622 | ZA 2004-1054 | 20040209 |
| US 20040235909 | A1 | 20041125 | US 2004-803798 | 20040318 |
| US 7001923 | B2 | 20060221 | | |
| US 20050009920 | A1 | 20050113 | US 2004-846152 | 20040514 |
| US 7037940 | B2 | 20060502 | | |
| US 20060116374 | A1 | 20060601 | US 2005-244427 | 20051005 |
| US 7368473 | B2 | 20080506 | | |
| US 20060122183 | A1 | 20060608 | US 2005-244324 | 20051005 |
| US 7345094 | B2 | 20080318 | | |
| US 20080214655 | A1 | 20080904 | US 2008-9641 | 20080118 |
| US 7671092 | B2 | 20100302 | | |
| US 20080242702 | A1 | 20081002 | US 2008-77729 | 20080320 |
| PRIORITY APPLN. INFO.: | | | US 2001-304252P P | 20010710 |

| | | |
|---|---|---|
| US 2002-361936P | P | 20020306 |
| US 2002-361946P | P | 20020306 |
| US 2002-193075 | A2 | 20020710 |
| US 2002-193639 | A2 | 20020710 |
| EP 2002-746947 | A3 | 20020710 |
| EP 2002-752238 | A3 | 20020710 |
| US 2004-803798 | A1 | 20040318 |
| US 2004-846152 | A1 | 20040514 |
| US 2005-244324 | A1 | 20051005 |
| US 2005-244427 | A3 | 20051005 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 139:323341
GI



I



II

AB The title compds. I [wherein Y = a single bond, phenylene, or (un)substituted hydrocarbyl, etc.; R1 and R2 = independently (un)substituted aryl; R3-R6 = independently H, (un)substituted aliphatic group, or aryl; Z = O or S; etc.] and pharmaceutically acceptable salts thereof are prepared as taxol enhancers for treatment of cancer. For example, the compound II was prepared in a multi-step synthesis. Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of I in combination with taxol or an analog of taxol. II showed synergistic anticancer activity with paclitaxel in rat.
OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

=> d his

(FILE 'HOME' ENTERED AT 16:53:25 ON 17 MAR 2010)

FILE 'REGISTRY' ENTERED AT 16:53:38 ON 17 MAR 2010
L1 STRUCTURE UPLOADED
L2 2 S L1 SSS
L3 0 S L1 EXA
L4 102 S L1 FULL

FILE 'CAPLUS' ENTERED AT 16:54:56 ON 17 MAR 2010
L5 36 S L4
L6 11 S L5 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM?)/TI
L7 11 DUP REM L6 (0 DUPLICATES REMOVED)

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 44.34 | 240.79 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | -9.35 | -9.35 |

STN INTERNATIONAL LOGOFF AT 16:56:14 ON 17 MAR 2010